Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer

Marise R. Heerma van Voss, Farhad Vesuna, Kari Trumpi, Justin Brilliant, Cynthia Berlinicke, Wendy de Leng, Onno Kranenburg, Johan G. Offerhaus, Horst Bürger, Elsken van der Wall, Paul J. van Diest, Venu Raman

Research output: Contribution to journalArticle

Abstract

Identifying druggable targets in the Wnt-signaling pathway can optimize colorectal cancer treatment. Recent studies have identified a member of the RNA helicase family DDX3 (DDX3X) as a multilevel activator of Wnt signaling in cells without activating mutations in the Wnt-signaling pathway. In this study, we evaluated whether DDX3 plays a role in the constitutively active Wnt pathway that drives colorectal cancer. We determined DDX3 expression levels in 303 colorectal cancers by immunohistochemistry. 39% of tumors overexpressed DDX3. High cytoplasmic DDX3 expression correlated with nuclear ß-catenin expression, a marker of activated Wnt signaling. Functionally, we validated this finding in vitro and found that inhibition of DDX3 with siRNA resulted in reduced TCF4-reporter activity and lowered the mRNA expression levels of downstream TCF4-regulated genes. In addition, DDX3 knockdown in colorectal cancer cell lines reduced proliferation and caused a G1 arrest, supporting a potential oncogenic role of DDX3 in colorectal cancer. RK-33 is a small molecule inhibitor designed to bind to the ATP-binding site of DDX3. Treatment of colorectal cancer cell lines and patient-derived 3D cultures with RK-33 inhibited growth and promoted cell death with IC50 values ranging from 2.5 to 8 μM. The highest RK-33 sensitivity was observed in tumors with wild-type APC-status and a mutation in CTNNB1. Based on these results, we conclude that DDX3 has an oncogenic role in colorectal cancer. Inhibition of DDX3 with the small molecule inhibitor RK-33 causes inhibition of Wnt signaling and may therefore be a promising future treatment strategy for a subset of colorectal cancers.

Original languageEnglish (US)
Pages (from-to)28312-28326
Number of pages15
JournalOncotarget
Volume6
Issue number29
DOIs
StatePublished - 2015

Keywords

  • Colorectal cancer
  • DEAD-box RNA helicases
  • Small molecule inhibitors
  • Wnt signaling
  • β-catenin

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Heerma van Voss, M. R., Vesuna, F., Trumpi, K., Brilliant, J., Berlinicke, C., de Leng, W., Kranenburg, O., Offerhaus, J. G., Bürger, H., van der Wall, E., van Diest, P. J., & Raman, V. (2015). Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer. Oncotarget, 6(29), 28312-28326. https://doi.org/10.18632/oncotarget.4873